Back

Valvular changes following anthracycline therapy: is it time to look beyond ejection fraction?

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Cardio-oncology 1 Cardio-Oncology ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Associate Professor Michal Laufer-Perl

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

5 More presentations in this session

Presentation thumbnail
Prevalence of RV dysfunction in patients under cardiotoxic chemoterapy: a preliminary analysis
Doctor S. Maltes (Lisbon, PT)
Abstract Slides
Presentation thumbnail
The effect of ACE-I/ARBs and beta blockers on the development of cardiotoxicity in patients with breast cancer
Doctor G. Umadat (Jacksonville, US)
Abstract Slides
Presentation thumbnail
Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis - report from an international registry
Doctor P. Guedeney (Paris, FR)
Abstract Slides
Presentation thumbnail
Emergency department cardiovascular disease encounters and associated mortality in patients with cancer: a study of 20.6 million records from the USA
Doctor O. Kobo (Hadera, IL)
Abstract Slides
Presentation thumbnail
Cardio-Oncology: a medical specialty in constant growth and evolution. the 10-year experience of the first cardio-oncology service in the United Kingdom
Doctor M. Andres (London, GB)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology 1

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources